Navigation Links
In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting
Date:2/20/2009

SANTA MONICA, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that Matthew Schissler, founder and CEO, in an interview with analyst Francis Gaskins, provided details of the Company's special shareholder meeting in March.

The complete interview is available at: http://www.stoxrox.com/cbai-2-18-09-e.mp3

In the interview, Mr. Schissler explains why the Company is asking for an increase in authorized shares. He explains that authorized is "vastly different from outstanding" and the Company currently has no commitments or understandings for the issuance of additional outstanding shares other than those currently on file at the SEC.

"Our goal is to be ahead of the game. We want to grow the Company into a global leader in the storage of stem cells and that includes the ability to act and react quickly. We also want to benefit from what we believe will be greatly increased research in this sector. This lets us control our destiny," Mr. Schissler said. Asked why Cord Blood America is asking for such a large increase in authorized shares, the Company's founder said "this is a time-consuming, costly process and we only want to do it once in the Company's history."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

        CONTACT:
        Paul Knopick
        E & E Communications
        949/707-5365
        pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. In Analyst Interview, Cord Blood America Says Stem Cells Now Front and Center for Researchers and Investors
2. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
3. EntreMed to Present at the New York Society of Security Analysts Industry Conference
4. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
5. Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts
6. Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts
7. Global Agricultural and Environmental Diagnostics Market to Reach $2.4 Billion by 2012, According to New Report by Global Industry Analysts
8. World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
9. World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc.
10. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts
11. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):